Get the Stockscreener App
24.38
1.33%
0.32
Pre-market:
24.66
0.28
+1.15%
Moderna Inc stock is traded at $24.38, with a volume of 9.67M.
It is up +1.33% in the last 24 hours and down -1.06% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$24.06
Open:
$24.33
24h Volume:
9.67M
Relative Volume:
0.94
Market Cap:
$10.45B
Revenue:
$5.06B
Net Income/Loss:
$-2.22B
P/E Ratio:
-4.189
EPS:
-5.82
Net Cash Flow:
$-3.96B
1W Performance:
-9.80%
1M Performance:
-1.06%
6M Performance:
-47.94%
1Y Performance:
-80.00%
1-Day Range:
$23.95
$24.98
1-Week Range:
$23.70
$28.52
52-Week Range:
$23.15
$170.47
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
24.38 | 10.45B | 5.06B | -2.22B | -3.96B | -5.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.60 | 128.25B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.67 | 63.70B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
569.12 | 39.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
258.35 | 33.27B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
235.94 | 27.58B | 3.81B | -644.79M | -669.77M | -6.24 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Collar Capital Management LLC Invests $898,000 in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Banque Transatlantique SA Purchases New Stake in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Axa S.A. Sells 38,456 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
PDT Partners LLC Has $280,000 Stake in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna claims to have combined flu and COVID-19 vaccines - CBS News
Kovitz Investment Group Partners LLC Sells 40,925 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna study shows immune response in older adults for a new combo flu and COVID-19 shot - kotatv.com
Moderna Stock: Analyst Estimates & Ratings - Nasdaq
How effective will Moderna's combo Covid and flu mRNA shot be? - KSNV
Moderna, Inc. (NASDAQ:MRNA) Stake Lifted by Northern Trust Corp - MarketBeat
Moderna (MRNA) and Pfizer/BioNTech Vaccines Under FDA Review - GuruFocus
FDA advisory panel to discuss makeup of updated COVID shots - Seeking Alpha
MRNA Sees Surge in Options Activity with Notable Imbalance | MRNA Stock News - GuruFocus
June 27th Options Now Available For Moderna (MRNA) - Nasdaq
Moderna's Combo Flu and COVID Shot Shows Promise - El Paso Inc.
197,500 Shares in Moderna, Inc. (NASDAQ:MRNA) Bought by Cutter Capital Management LP - MarketBeat
Moderna to Present at Upcoming Bernstein's 41st Annual Strategic Decisions Conference (SDC) on May 29, 2025 | MRNA Stock News - GuruFocus
Moderna to Present at Upcoming Bernstein's 41st Annual Strategic Decisions Conference (SDC) on May 29, 2025 - The Derrick
RFK Jr. Takes Aim at Covid Shots for Kids, Worrying Vaccine Experts - Bloomberg
Moderna study shows immune response in older adults for a combo flu and COVID-19 shot - yoursun.com
Combo flu and COVID-19 shot shows promise in new Moderna study - LiveNOW from FOX
US FDA advisers to discuss COVID-19 vaccine recommendations on May 22 - marketscreener.com
Moderna Vaccine Study - Tulsa World
Cantor Fitzgerald L. P. Purchases New Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Dimensional Fund Advisors LP Has $69.34 Million Stock Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
BLI Banque de Luxembourg Investments Takes Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
GraniteShares adjusts Moderna ETP in upcoming consolidation By Investing.com - Investing.com UK
This Week's Healthcare Earnings: Moderna, CVS, Hims & Hers - Law360
Moderna, Pharma Stocks Fall as FDA Names Industry Critic as Top Vaccine Regulator - Barron's
Moderna Sharpens Pipeline Focus as COVID-19 Vaccine Demand Ebbs in Q1 - The Globe and Mail
Redburn Atlantic Adjusts Moderna Price Target to $53 From $52, Maintains Neutral Rating - marketscreener.com
Public Employees Retirement Association of Colorado Trims Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
mRNA Vaccines: Evolving Pipelines Across Infectious Disease, Oncology & Rare Disorders - openPR.com
Moderna, Inc. (NASDAQ:MRNA) Stock Position Increased by Lido Advisors LLC - MarketBeat
Price T Rowe Associates Inc. MD Has $44.62 Million Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Envestnet Asset Management Inc. Lowers Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
On the Move: Moderna's Cronin Moves to Medtronic Diabetes - O'Dwyer's PR
Ex-Moderna brand chief Kate Cronin joins Medtronic Diabetes as marketing lead - Medical Marketing and Media
Moderna Sharpens Pipeline Focus As COVID-19 Vaccine Demand Ebbs In Q1 - Barchart.com
The Manufacturers Life Insurance Company Acquires 267,990 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna Stock Crumbles As Vaccine Troubles Rattle Its Topline - MSN
Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Pinebridge Investments L.P. - MarketBeat
Moderna Q1 Earnings Ahead: Analysts expect loss amid increased regulatory scrutiny - MSN
Moderna, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – MRNA - ACCESS Newswire
Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Aquatic Capital Management LLC - MarketBeat
UBS Analyst Lowers Price Target for MRNA, Maintains Buy Rating | - GuruFocus
XTX Topco Ltd Decreases Stock Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Barclays Lowers Price Target on Moderna (MRNA) to $40.00 | MRNA Stock News - GuruFocus
Moderna Pivots To Increase Focus On Cancer Amid US Vaccine Policy Changes - insights.citeline.com
Susquehanna Fundamental Investments LLC Invests $16.04 Million in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Moderna Inc Stock (MRNA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| SAGAN PAUL | Director |
Mar 03 '25 |
Buy |
31.76 |
31,620 |
1,004,251 |
312,027 |
| Klinger Shannon Thyme | Chief Legal Officer |
Dec 09 '24 |
Sale |
44.68 |
529 |
23,637 |
20,446 |
5.73%
1.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):